Back Back
Cell No. : Cell Name
RCB5391 : R52_Spike  update : 2022/09/06
Comment from the depositorThis cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone R52).
Terms and conditions1)There is no restriction regarding use for basic researches. 2) The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. 3) In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (J Biol Chem 2021 296:100346) designated by the DEPOSITOR is required.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor MURANO, Kensaku
Originator MURANO, Kensaku
Year of deposit 2021
Cloning (depositor) Yes
_Date (depositor) 2020.06
_Method (depositor) limiting dilution
Animal mouse x mouse < Hybrid
Classification hybrid cells
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_A7AF
hybridoma Fusion_cell_1 name SP2/0-Ag14 (RCB0209)
Fusion_cell_1 strain mouse, BALB/c
Fusion_cell_2 name spleen
Fusion_cell_2 strain mouse, Balb/c
Fusion_cell_2 gender Female
Fusion method electro cell fusion, HAT, ELISA
Antibody name R52
Subclass IgG1(Kappa)
Immunogen MBP-RBD (Receptor binding domain of spike protein)
Antigen_name SARS-CoV-2 Spike
Antigen_m.w. 200 kDa (SDS-PAGE)
Antigen_character glycosylated protein
Antigen_epitope 549-TGVLTESNKKFLPFQQFGRD-568 of spike protein RBD
Antigen_positive SARS-CoV-2 infection to VeroE6/TMPRSS2 cells
deposit info
lot info
Medium Medium List
Culture type Suspension cells Suspension cells
Medium and additives Hybridoma Serum-Free Medium (FUJIFILM Wako #081-10381) + 1ng/mL IL-6 (Recombinant Human Interleukin-6, PeproTech #200-06) Hybridoma Serum-Free Medium + 1ng/mL human IL-6
Antibiotics Free
Passage method dilution
Designated culture dish non-coated dish, non-coated fask
Culture information Passage cell No 1-2×10^(5) cells/mL
Passage ratio 1 : 10 split
SC frequency Subculture : every day or every other day (< 1.0×10^(6) cells/mL) Subculture : 3 times/week
Temperature 37 ℃ 37 ℃
CO2 concentration 5 % 5 %
Freeze medium CELLBANKER 1 (Zenoaq #CB011) CELLBANKER 1
Freezing method Slow freezing
Mycoplasma (-)
Antibody subclass IgG1(Kappa)
Saturation density 1.5×10^(6) cells/mL
Doubling time 15 hr
deposit info
lot info
Reference information Reference 2
User's Publication 0

To topTop
13648  Guo Y, Kawaguchi A, Takeshita M, Sekiya T, Hirohama M, Yamashita A, Siomi H, Murano K.  Potent mouse monoclonal antibodies that block SARS-CoV-2 infection  J Biol Chem  2021  296:100346  PubMed ID: 33524396   DOI: 10.1016/j.jbc.2021.100346
15882  Murano K, Guo Y, Siomi H.  The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines  Biochem Soc Trans  2021  Dec 2;BST20210859  PubMed ID: 34854887   DOI: 10.1042/BST20210859

To topTop
User's Publication

Back Back Return Top Page